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Background: Bacterial superantigens are potent T cell activators that can activate T cells with specificity for
antigens of the central nervous system (CNS). In this study, we compared the effect of two S. aureus strains on
experimental autoimmune encephalomyelitis (EAE) development. C57BL/6 female mice were infected with S. aureus
ATCC 51650, which produces toxic shock syndrome toxin 1 (TSST-1+) or S. aureus ATCC 43300, which does not
produce toxins (TOX-). Three days later, the animals were subjected to EAE induction by immunization with myelin
oligodendrocyte glycoprotein (MOG). The weight variation, disease incidence and clinical score were recorded daily.
Cytokines and Foxp3+ regulatory T cells in the brain were evaluated during the acute disease phase. Cytokines and
Foxp3+ regulatory T cells in the spleen and histopathological analysis of the CNS were assessed during the chronic stage.
Results: Previous infection with both strains similarly decreased the clinical score; however, only the TSST-1+ strain clearly
diminished inflammation in the CNS. The infections also modulated cytokine production in the spleen and CNS. Reduced
production of IL-5 and IL-10 was detected in MOG-stimulated spleen cultures in the TOX- and TSST-1+ infected groups,
respectively. In S. aureus stimulated cultures, there was an increased production of IFN-γ and IL-10 in both infected groups
and an increased level of IL-5 in the TSST-1+ group. CNS infiltrating cell cultures from previously infected mice produced
less IL-17 in response to MOG and more IFN-γ in response to S. aureus stimulation.
Conclusions: These results indicated that both strains attenuated clinical EAE manifestations, but only TSST-1 clearly
decreased CNS inflammation.
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Multiple sclerosis (MS) is a demyelinating disease of the
central nervous system (CNS), which is mainly mediated
by T cells that are specific for the myelin self-antigen.
These autoreactive T cells are generated in the periphery
and cross the blood-brain barrier to the brain paren-
chyma where they initiate an autoimmune attack on the
myelin sheath [1,2]. MS has been histopathologically
characterized by four main findings: inflammation, de-
myelination, axonal damage and gliosis. Much of the* Correspondence: sartori@ibb.unesp.br
1Department of Microbiology and Immunology, Biosciences Institute, Univ
Estadual Paulista (UNESP), Distrito de Rubião Júnior s/n, 18618-000 Botucatu,
São Paulo, Brazil
Full list of author information is available at the end of the article
© 2014 França et al.; licensee BioMed Central
Commons Attribution License (http://creativec
reproduction in any medium, provided the orknowledge about MS is derived from studies on experi-
mental autoimmune encephalomyelitis (EAE). This dis-
ease can be induced in a variety of animals, particularly
in rodents, providing models of acute monophasic, relaps-
ing remitting and chronic progressive CNS inflammation
[2]. Although many gaps still exist in the understanding of
MS immunopathogenesis, it is widely believed that this
complex pathology involves both host genetic and envir-
onmental factors [1]. Infectious disease agents can modu-
late autoimmune diseases in many different ways, such as
triggering these pathologies or, contrarily, preventing their
development [3,4]. S. aureus is one of the most prevalent
pathogens in the human population; colonizing the anterior
nares of 20-60% of the population. These Gram-positiveLtd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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scesses and impetigo, or serious invasive infections such as
septic arthritis, osteomyelitis, endocarditis [5-7] and food
poisoning [8]. Most S. aureus strains secrete an array of
extracellular enzymes, which facilitate tissue destruction
and spreading and membrane damaging toxins that cause
cytolytic effects on host cells and tissue damage [9,10].
Currently, 20 serologically distinct staphylococcal super-
antigens (SAgs) have been described, including TSST-1
and the enterotoxins A-E and G-J [11]. S. aureus SAgs can
activate a high proportion of T cells due to their ability to
bind to both MHC class II molecules in antigen present-
ing cells and specific V-β regions in the T cell receptor
[1,12]. This activation results in the polyclonal stimulation
of T cells and an elevated production of proinflammatory
cytokines [1,13]. Experimental and epidemiological evi-
dence support the theory that S. aureus that produces
SAgs may be implicated in the genesis of MS [1,14,15]. In
this context, the main objective of this investigation was
to compare the effects of two S. aureus strains, one strain
that produces TSST-1 and an other strain that does not
produce any SAgs, on EAE development.
Results
Clinical disease severity is reduced by a previous
S. aureus infection
The EAE control group (mice immunized with myelin
oligodendrocyte glycoprotein (MOG) without a previ-
ous S. aureus infection) presented the expected clinical
alterations. These animals showed a reduction in body
weight (Figure 1a), which coincided with the highest
clinical scores observed during the acute phase of
the disease (Figure 1b). Previous infection with both
S. aureus strains prevented this reduction in body
weight (Figure 1a) and also decreased the clinical
scores (Figure 1b and 1c). This protective effect on disease
severity was also detected when the disease incidence
was examined. As shown in Table 1, 89% of the animals
from the EAE control group were ill whereas the inci-
dence in the TOX-/EAE and TSST-1+/EAE groups was
67% and 36%, respectively.
Inflammation intensity in the CNS is reduced by previous
infection with S. aureus TSST-1
Typical lesions characterized by intense inflammatory
infiltrates were observed in the brains (Figure 2a) and
lumbar spinal cords (Figure 3a) in the animals in the EAE
control group. Comparable findings were observed in ani-
mals that were infected with the TOX- strain prior to EAE
induction (Figures 2e and 3e). In contrast, the group that
was previously infected with the TSST-1+ strain presented
a very discrete inflammatory infiltration, which was
restricted to the perivascular region in the brain and
lumbar spinal cord (Figures 2c and 3c, respectively).Peripheral cytokine production is modulated by
S. aureus infections
Production of IFN-γ and IL-17 induced by MOG was
not affected by previous infection with either strain of S.
aureus, as illustrated in Figure 4a and 4b, respectively.
Significant reductions in IL-5 (Figure 4c) and IL-10
(Figure 4d) were observed in the groups that were pre-
viously infected with TOX- and TSST-1+, respectively.
Some clear differences were observed in the levels of
these cytokines when splenic cultures were stimulated
with S. aureus antigen (SAC). IFN-γ and IL-10 production
was significantly elevated in the previously infected group
compared to the EAE group (Figure 5a and d, respectively).
IL-5 production by the TSST-1+ group was also signifi-
cantly higher compared to the EAE and TOX-/EAE
groups (Figure 5c). Similar levels of IL-17 were found
in the three experimental groups (Figure 5b).
In situ (CNS) cytokine production is modulated by
previous S. aureus infections
CNS infiltrating cells from the EAE, TSST-1+/EAE and
TOX-/EAE groups were cultured in the presence of MOG
or SAC. In MOG-stimulated cultures, the production of
IFN-γ, IL-5 and IL-10 was similar between the 3 groups
(Figure 6a, c and d). However, previously infected animals
produced less IL-17 than the animals in the EAE control
group (Figure 6b). In the SAC-stimulated cultures, IFN-γ
levels were higher in previously infected mice compared
to the mice in the EAE control group. No differences were
observed in the IL-17, IL-5 and IL-10 production in these
cultures. These results are shown in Figure 6f, g and h,
respectively.
Previous infection with TOX- S. aureus down-modulated
the percentage of Foxp3+ regulatory T cells in the CNS
Animals with EAE presented a significant increase in
the frequency of splenic CD4+ CD25+ Foxp3+ T cells
compared to the negative control group (Figure 7a).
Infections with TSST-1+ and TOX- strains before EAE
induction did not alter the percentage of these T cells
in this peripheral lymphoid organ (Figure 7a). The
presence of these regulatory cells was concomitantly
evaluated in the CNS. As shown in Figure 7b, the
number of CD4+ CD25+ Foxp3+ T cells was similar
in the EAE and TSST-1+ groups, but was significantly
lower in the group that was previously infected with
the TOX- strain. Histopathological analysis indicated
that the brains from the mice that were solely in-
fected with TOX- and were not subjected to EAE in-
duction presented abundant inflammatory infiltrates
15 days after infection. In contrast to this result, mice
infected with the TSST-1+ strain presented no inflam-
mation in the corresponding time period (Figure 7d
and c, respectively).
Figure 1 Effect of previous infection with S. aureus in body weight and clinical score. C57BL/6 mice were infected with S. aureus TSST-1+ and
TOX-. Three days later, the animals were subjected to EAE induction, and their body weight and clinical scores were evaluated daily. The profile of the
animals’ weight during 30 days (a), clinical score (b) and maximum clinical score (c). Data are presented as the mean ± SE of 9-12 mice and are
representative of two independent experiments, p < 0.05. The statistical analysis (ANOVA or ANOVA on Ranks with Dunn’s method) indicates
significant differences between EAE and both infected groups. These differences began on day 15 and remained significant until day 30. No
differences were observed between the two infected groups.
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Multiple sclerosis (MS) is a demyelinating disease of the
central nervous system (CNS) that is characterized by an
autoimmune inflammatory process involving myelin an-
tigens [2]. Experimental autoimmune encephalomyelitis
is currently the most widely accepted animal model to
investigate this pathology. Epidemiological studies have
identified several environmental risk factors that contrib-
ute to the development of this disease, such as viral in-







EAE (n = 9) 8/9 89 p = 0.051
TSST-1+/EAE (n = 10) 4/10 36
TOX-/EAE (n = 12) 8/12 67[16]. Although SAgs have been implicated in the patho-
genesis of different autoimmune diseases, such as type I
diabetes, Kawasaki disease and MS [17], their effects
have not been systematically tested in these pathologies.
In the present investigation, we evaluated the effect of
previous infections with S. aureus on EAE development.
To achieve this, female C57BL/6 mice were infected
with 2 distinct S. aureus strains; one strain was a produ-
cer of the TSST-1 toxin (ATCC 51650), and the other
strain did not produce any SAgs (ATCC 43300). Three
days after infection, the animals were subjected to EAE
induction, and the disease evolution was compared with
a control group that had not been infected before EAE
induction. Previous inoculation with both strains clearly
induced a protective effect that was characterized by the
appearance of a much more benign disease. Previously
infected animals did not lose weight during the acute
phase and also presented a less severe sickness with
lower clinical scores. In addition to these less serious
Figure 2 Inflammation in the brain of mice with EAE: effect of previous infection with S. aureus. C57BL/6 mice were infected with
S. aureus TSST-1+ and TOX-, and 3 days later, they were subjected to EAE induction. Brain inflammatory infiltrates in mice with EAE (a, b), mice
previously infected with S. aureus TSST-1 strain subjected to EAE (c, d) and mice previously infected with S. aureus TOX- strain subjected to EAE
(e, f) were evaluated 30 days after disease induction. The panel is representative of 6-7 animals/group. Magnification is 10 x and 100 x in the left
and right panel, respectively.
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cidence. A comparison of all of these parameters indi-
cated that the TSST-1+ strain was more protective than
the TOX- strain. In addition, the first signals of paralysis
in the TSST-1+ infected group were delayed. In this
group, these clinical symptoms appeared only on the
21st day after EAE induction, compared to the EAE
control group, which exhibited symptoms by the 14th
day. To examine the mechanisms by which these two
S. aureus strains protected against EAE development,
cytokine production by the spleen and CNS infiltrating
cell cultures were concomitantly evaluated. The similar
IFN-γ and IL-17 levels in the MOG-stimulated spleen
cultures from the three experimental groups suggest that
previous infection is not down-regulating the peripheralproduction of encephalytogenic cytokines. However, a sig-
nificant down-regulation of IL-5 and IL-10 was observed
in the TOX-/EAE and TSST-1+/EAE-infected animals,
respectively. In this context, we hypothesized that this
decreased production of anti-inflammatory cytokines
was due to a migration of specific T cell clones from the
periphery to the CNS. However, an evaluation of IL-5
and IL-10 production by cells infiltrating the CNS was
not consistent with this interpretation. Interestingly,
there was a lower production of IL-17 in the CNS of
mice that were previously infected with S. aureus com-
pared to the positive control animals, i.e., the EAE group.
We believe that this is an important finding because IL-17
is described as a relevant mediator of EAE and MS immu-
nopathogenesis [18,19]. Because the peripheral production
Figure 3 Inflammation in the spinal cord of mice with EAE: effect of previous infection with S. aureus. C57BL/6 mice were infected with
S. aureus TSST-1+ and TOX-, and 3 days later, they were subjected to EAE induction. The lumbar spinal cord inflammatory infiltrates in mice with
EAE (a, b), mice previously infected with S. aureus TSST-1 strain subjected to EAE (c, d) and mice previously infected with S. aureus TOX- strain
subjected to EAE (e, f) were evaluated 30 days after disease induction. The panel is representative of 6-7 animals/group. Magnification is 10 x and
100 x in the left and right panel, respectively.
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three groups, this lower local level of IL-17 could be due
to a decreased migration of Th17-specific clones to the
CNS or to a local down-modulation of IL-17 production.
To test the last possibility, we analyzed the cytokine
production specifically induced by S. aureus (SAC) in
the periphery (spleen) and in the CNS. Previous infection
was associated with an accentuated immune response
characterized by a significant production of IFN-γ, IL-5
and IL-10. SAC-specific clones capable of producing
anti-inflammatory cytokines could migrate to the CNS
and down-modulate IL-17 production. A theoretical
basis for this possibility was found in the literature.
Initially described as a product of Th2 cells, IL-10 is
now recognized as being secreted by nearly every celltype of the immune system and is able to inhibit the in-
flammatory process [20]. In the context of MS and
EAE, IL-10 clearly elicits beneficial effects on these
diseases. In MS patients, for example, IL-10 levels are
increased in the serum during disease remission [21].
In addition, the efficacy of IFN-β and glatiramer acet-
ate, two widely employed MS treatments, is partially
attributed to the induction of IL-10 [21-23]. Genetic
studies using the EAE model also showed that IL-10
deletion enhanced EAE disease severity while over-
expression of this cytokine protected mice [24]. More-
over, treatment of EAE with a herpes simplex virus type 1
vector expressing IL-5 ameliorated EAE and decreased
the number of infiltrating lymphocytes in the brain [25].
Similarly, treatment of experimental autoimmune neuritis
Figure 4 Production of cytokines by spleen cells stimulated with MOG. C57BL/6 mice were infected with S. aureus strains, and 3 days later,
they were subjected to EAE induction. Cytokine production was tested 30 days after EAE induction. IFN-γ (a), IL-17 (b), IL-5 (c) and IL-10 (d)
production were assayed in spleen cell cultures that were re-stimulated in vitro with MOG. Data are expressed as the mean ± SE of 5-12 mice.
Different letters represent significant differences between the groups. The statistical analysis (ANOVA or ANOVA on Ranks with Dunn’s method)
indicate significant differences between EAE and both infected groups, p<0.05.
Figure 5 Production of cytokines by spleen cells stimulated with SAC. C57BL/6 mice were infected with S. aureus strains, and 3 days later,
they were subjected to EAE induction. Cytokine production was tested 30 days after EAE induction. IFN-γ (a), IL-17 (b), IL-5 (c) and IL-10 (d)
production were assayed in spleen cell cultures that were re-stimulated in vitro with SAC. Data are expressed as the mean ± SE of 5-12 mice.
Different letters represent significant differences between the groups. The statistical analysis (ANOVA or ANOVA on Ranks with Dunn’s method)
indicate significant differences between EAE and both infected groups, p<0.05.
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Figure 6 Production of cytokines by CNS infiltrating cells stimulated with MOG or SAC. C57BL/6 mice were infected with S. aureus strains,
and 3 days later, they were subjected to EAE induction. Cytokine production was tested 19 days after EAE induction (acute phase) in CNS cell
cultures. IFN-γ (a), IL-17 (b), IL-5 (c) and IL-10 (d) production were assayed in cultures that were re-stimulated in vitro with MOG. IFN-γ (e), IL-17
(f), IL-5 (g) and IL-10 (h) production were assayed in cultures that were re-stimulated in vitro with SAC. Data are expressed as the mean ± SE of
5-12 mice. Different letters represent significant differences between groups. Statistical analysis (ANOVA or ANOVA on Ranks with Dunn’s method)
indicates significant differences between EAE and both infected groups, p< 0.05.
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sis, weight loss, demyelination as well as infiltration of
Th1, Th17 and Tc cells and macrophages in nerves [26].
Despite the significant peripheral production of IL-10 in
mice infected with both strains and IL-5 in mice infected
with the TOX- strain, the levels of these cytokines were
statistically similar in the CNS of the three experimental
groups. Taken together, the cytokine results suggest that
down-modulation of IL-17 in the brain was not mediated
by IL-10 or IL-5 production in the CNS. Considering that
the balance between Th17 and regulatory T cells is critical
in autoimmune diseases [27] and that a high frequency of
regulatory T cells migrate to the CNS during EAE recovery
[28,29], we analyzed the frequency of Foxp3+ regulatory T
cells in the spleen and at the site of inflammation. The pro-
portion of CD4+ CD25+ Foxp3+ cells in the spleen and
CNS was significantly elevated in mice with EAE, as shown
in this study and previous studies [18,28]. The suppositionthat the protection by previous S. aureus infection was
mediated by an increased number of Foxp3+ Treg cells
was not confirmed. Previous infections did not increase
the number of Foxp3+ cells in either the spleen or the
CNS. In contrast with our expectations, the number of
CD4+ CD25+ Foxp3+ cells was significantly decreased in
the TOX-/EAE group. This finding was consistent with
the presence of a strong inflammatory process in the CNS
of this group, although the animals were clearly protected
from the disease. The histopathological analysis of the in-
fected animals that were not subjected to EAE induction
showed that infection with the TOX- strain, but not with
the TSST-1strain, triggered a clear inflammatory process
in the brain. Taken together, these results suggest that the
TOX- strain or its secreted components can cross the
blood-brain barrier and elicit a local accumulation of
inflammatory cells. Penetration of S. aureus across the
blood-brain barrier has recently been described [30]
Figure 7 Frequency of regulatory T cells in the spleen and CNS of mice with EAE: effect of previous infections with S. aureus. The
percentage of CD4 + CD25 + Foxp3+ T cells was evaluated in the spleen (a) and CNS (b). Brain inflammatory infiltrates in mice previously infected
with S. aureus TSST-1 (c) or with S. aureus TOX- strain (d) were evaluated 15 days after the infection. Data were expressed as the mean ± SE of
6-9 mice in Figures 7a and b. Different letters represent significant differences between groups. The statistical analysis (ANOVA with Dunn’s or
Holm-Sidak method) indicates significant differences between EAE and both infected groups, p<0.05. Micrographs (c and d) are representative of
5-6 animals/group.
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lower number of Foxp3+ cells in TOX-infected animals
could be due to a “dilutive effect” caused by the infil-
tration of phagocytic cells that are trying to eliminate a
local S. aureus infection. Our initial hypothesis that the
TSST-1 strain could increase disease severity due to its
superantigenicity was not confirmed by our findings.
Considering the various parameters (lower clinical score,
lower disease incidence and very discrete inflammation in
the CNS), we believe that this strain was more protective
than the TOX- strain. Thus, we hypothesize that these
two S. aureus strains are protecting the animals from EAE
development using different molecular mechanisms or
more than one immunomodulatory via. In this scenario,
we could imagine that the TSST-1 strain was more effect-
ive because it employed a stronger immunoregulatory
mechanism or multiple mechanisms. In this sense, it has
been demonstrated that the TSST-1 toxin was able to
cause apoptosis of myelin T cell clones [31]. However,
we could not make a direct comparison of these results
with the literature because there were no experimental
approaches similar to the one employed by our study.
Thus, this is the first direct demonstration that an S. aureusinfection was able to decrease the severity of EAE. Further
studies are necessary to highlight the protective mecha-
nisms that are triggered by S. aureus infection to protect
against EAE development. It will be relevant to establish if
these two strains present differences related to dissemin-
ation in the CNS as well as in the secretion of extracellular
adherence protein (Eap). This protein is endowed with the
ability to prevent EAE development by inhibiting infiltra-
tion of inflammatory cells into the CNS [32].
Conclusion
These findings indicate that both TSST-1+ and TOX-
S. aureus strains were able to attenuate EAE severity. They
also suggest that, in contrast to our expectations, the TSST-
1+ strain was more protective than the TOX- strain.
Methods
Experimental design
Mice were infected with S. aureus strains. Three days later,
they were subjected to EAE induction by immunization
with MOG, which was emulsified with complete Freund’s
adjuvant. The effect of the infections on EAE development
was evaluated by a clinical follow-up (weight variation and
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CNS. The potential immunoregulatory effect of the infec-
tions was confirmed by cytokine production and quantifi-
cation of Foxp3+ regulatory T cell. Cell cultures were
stimulated with MOG and S. aureus Cowan I (SAC). Cy-
tokines and Foxp3+ regulatory T cells were evaluated in
the CNS during the acute disease phase, whereas cytokine
production by the spleen and brain and lumbar spinal
cord histopathological analysis were performed during the
chronic phase. An additional histopathological analysis
was performed in the brains of the mice that were solely
infected (15 days of infection).
Animals
C57BL/6 female mice (8-10 weeks old) were purchased
from CEMIB (UNICAMP, São Paulo, SP, Brazil). The
animals were provided with sterilized food and water
ad libitum. The mice were manipulated according to
the ethical guidelines adopted by the Brazilian College
of Animal Experimentation. All of the experimental
protocols were approved by the local Ethics Committee
(Ethics Committee for Animal Experimentation, Bioscience
Institute, Univ. Estadual Paulista).
Bacterial strains: growth conditions and mice infection
Two Staphylococcus aureus strains obtained from the
American Type Culture Collection (ATCC) were used in
this study. The ATCC 51650 strain was characterized by
TSST-1 production (TSST-1+), while the ATCC 43300
did not produce any toxin (TOX-). These strains were
initially cultured in blood agar and incubated at 37°C for
24 h. Isolated colonies were inoculated into brain heart
broth (BHI, Merck) and incubated at 37°C for 24 h. The
bacteria were collected by centrifugation, washed three
times and resuspended in cold sterile saline as previously
described by França et al., 2009 [33]. The animals were in-
traperitoneally injected with 300 μL of the bacterial suspen-
sions. The bacterial load in the blood was confirmed 3 days
after infection and was found to be similar for both strains.
EAE induction
MOG35-55 peptide (MEVGWYRSPFSRVVHLYRNGK)
was synthesized by Proteimax, São Paulo, Brazil. EAE was
induced as previously described (Zorzella-Pezavento et al.,
2013). Briefly, the mice were immunized subcutaneously
with 150 μg of MOG35–55 peptide emulsified in CFA
containing 400 μg of BCG. The mice also received 2
doses of 200 ng of Bordetella pertussis toxin (Sigma)
intraperitoneally 0 and 48 h after immunization. The
animals were examined daily and the disease intensity
was graded as: 0 - no disease, 1 - limp tail, 2 - weak/
partially paralyzed hind legs, 3 - completely paralyzed
hind legs, 4 - complete hind and partial front leg paralysis,
5 - complete paralysis/death.CNS-Infiltrating Cell Isolation
The mice were anesthetized with ketamine/xylazine and
perfused with 10 mL of saline solution. The brain and
spinal cord were excised, macerated, and maintained in
4 mL of RPMI (Sigma) supplemented with 2.5% collage-
nase D (Roche) at 37°C in a 5% CO2 incubator. Forty-five
min later, the suspensions were washed in RPMI and cen-
trifuged at 450 × g for 15 min at 4°C. The cells were resus-
pended in 37% percoll (GE Healthcare) and gently laid
over 70% percoll in tubes of 15 mL. The tubes were cen-
trifuged at 950 × g for 20 min with the centrifuge breaks
turned off. After centrifugation, the ring containing the
mononuclear cells was collected, washed in RPMI, and
centrifuged at 450 × g for 5 min. The cellular suspensions
were then resuspended in complete RPMI medium, quan-
tified, and analyzed.
Cell culture conditions and cytokine assays
CNS-infiltrating cells and spleen cells were adjusted to
2 × 105 cells/mL and 5 × 106 cells/mL, respectively, in
RPMI medium supplemented with 5% fetal calf serum,
20 mM glutamine and 40 IU/mL of gentamicin. Cell
cultures were stimulated with MOG (20 μg/mL) or SAC
(PANSORBIN®, Calbiochem®) (1/2500). Cytokine levels
in the culture supernatants were evaluated 48 h later
by enzyme-linked immunosorbent assay (ELISA) using
IFN-γ, IL-5 and IL-10 BD OptEIA Sets (Becton Dickinson)
and IL-17 (R&D Systems, Minneapolis, MN, USA). The
assays were performed according to the manufacturer’s
instruction.
Proportion of CD4 + CD25 + Foxp3+ T Cells
Spleen cells were collected and the red blood cells were
lysed with Hank’s buffer containing NH4Cl. Cells from the
spleen and CNS were adjusted to 2.5 × 106 cells/100 μL.
These cells were then incubated with 0.5 μg of fluorescein
isothyocianate (FITC) anti-mouse CD4 (clone GK1.5) and
0.25 μg of allophycocyanin (APC) anti-mouse CD25 (clone
PC61.5) for 20 min at room temperature. Staining for
Foxp3 was then performed using the phycoerythrin (PE)
anti-mouse/rat Foxp3 Staining Set (eBioscience, San Diego,
CA, USA) according to the manufacturer’s instructions.
After incubation, the cells were fixed in 1% paraformalde-
hyde.The cells were analyzed by flow cytometry using the
FACSCalibur (Becton Dickinson, San Jose, CA, USA) and
BD CellQuest Pro software (Becton Dickinson, San Jose,
CA, USA).
Evaluation of inflammatory infiltrates in the CNS
The brain and lumbar spinal cord were obtained 30 days
after EAE induction from infected and not infected ani-
mals. After fixation in 10% formaldehyde, the tissue sam-
ples were dehydrated in a graded ethanol series embedded
in a 100% paraffin block. Five micron-thick sections were
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eosin and were analyzed using a Nikon microscope. Histo-
pathologiocal analysis was also performed on brain samples
from infected mice that were not subsequently immunized
with MOG 15 days after infection.
Statistical analysis
Data were expressed as the mean ± SE. Comparisons
between groups were made using one-way ANOVA
with post-hoc Holm-Sidak methods for parameters
with normal distribution and using Kruskal-Wallis post-
hoc Dunn’s method for parameters with non-normal
distribution. The disease incidence was evaluated using
Chi-square test (p = 0.051). The significance level was
p < 0.05. Statistical analysis was achieved using SigmaStat
for Windows v. 3.5 (Systat Software Inc.).
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